DENVER, Jan. 26, 2022 /PRNewswire/ -- Infermedica, a leading digital health company, specializing in AI-powered solutions for symptom analysis and patient triage, today announces a $30 million Series B funding round, led by One Peak, and supported by previous investors: Karma Ventures, European Bank for Reconstruction and Development, Heal Capital, and Inovo Venture Partners. The new investment – which follows a Series A funding round just over a year ago – brings the company's total funding to $44 million. The capital will be used to support Infermedica in tackling some of the biggest issues facing healthcare through further development of their Medical Guidance Platform (MGP) and adding new modules to cover the full primary care journey. Infermedica will also increase their global commercial presence and expand their international, remote-first team of industry and medical experts.

More on Colorado Desk

• Pregis Expands Wind Energy Use, Advancing Progress Toward Net Zero by 2040
• Dr. Sheel Desai Solomon and Preston Dermatology Continue Awards Streak with Top Honors in 2026 Maggy Awards
• DOLA's Division of Property Taxation Encourages Eligible Colorado Seniors to Take Advantage of the 2026-27 Qualified Senior Primary Residence Classification Property Tax Reduction
• Jack and Sage Acquires Sustainable Apparel Brand Kastlfel, Expanding Premium Logo Wear Across National Parks and Ski Resorts
• Alpine Building Performance Launches First Free AI Inspection Forecaster for Real Estate Agents

"We are incredibly excited to back the Infermedica team as we share their vision of making healthcare more accessible and affordable by automating primary care. We have been particularly impressed with Infermedica's clinical safety and accuracy, best-in-class user experience, ease of deployment, and customer service. We believe the company has all the ingredients in place to become the global standard for using AI to support patients and healthcare providers in all steps of the primary care journey and we look forward to supporting Infermedica in its next phase of explosive growth."

---

Show All News | Report Violation